ArticleACS omega2026
Computational Selectivity Analysis of Aptamer toward Oxidized Low-Density Lipoprotein.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High target selectivity is a crucial factor in aptamer performance and practical applicability. The selectivity of four DNA aptamers (AP07, AP11, AP25, and AP29) toward oxidized low-density lipoprotein (oxLDL) was examined through computational prediction and experimental validation. Molecular dynamics simulations, combined with molecular mechanics generalized Born surface area (MM/GBSA) analysis, were employed to evaluate binding preferences against apolipoprotein (apo) B100 (apoB100) of native low-density lipoprotein (LDL), oxidized apoB100 of oxLDL, apoA1 of high-density lipoprotein (HDL), apoC1/apoE of very-low-density lipoprotein (VLDL), and albumin. Among the candidates, AP11 revealed the strongest predicted affinity and selectivity toward oxidized apoB100, exhibiting the lowest binding free energies of -344.52 ± 18.37 kcal/mol. Experimental validation using an aptamer-based electrochemical assay confirmed the computational predictions, with AP11 displaying high selectivity for the entire oxLDL and cross-reactivity below 6% toward LDL, HDL, VLDL, and albumin. Structural analysis indicated that AP11 preserves key conformational motifs upon complex formation, contributing to the oxLDL-aptamer interaction. This integrated computational-experimental framework provides a robust strategy for evaluating and optimizing aptamer selectivity toward complex biomolecular targets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.